The advances in diagnosis and treatment of nonsmall cell lung cancer with PET-CT

Abstract

Abstract: PET-CT plays a increasing important role in the treatment of lung cancer. Compared with CT, the advantage of PET-CT is obvious, which is more accuracy when determine a metastasis and identify inflammatory lesions. What′s more, on the basis of the accuracy staging, PET-CT change many strategies which were based on traditional image, resulting in improving the treatment effect. While the assessment and prediction of the efficacy by PET-CT also exerted an important influence on the formulation of treatment strategies.

Key words: Carcinoma, nonsmallcell lung, Fluorodeoxyglucose F18, Positronemission tomography, Tomography, Xray computed

ZHAO Xiang-Rong, ZHANG Yong, YU Yong-Hua. The advances in diagnosis and treatment of nonsmall cell lung cancer with PET-CT[J]. Journal of International Oncology, 2016, 43(2): 133-.

References

［1］ Cuaron J, Dunphy M, Rimner A. Role of FDGPET scans in staging, response assessment, and followup care for nonsmall cell lung cancer［J］. Front Oncol, 2013, 2: 208213. DOI:10.3389/fonc.2012.00208. ［2］朱有才, 杜开齐, 余党凡，等. 18FFDG PETCT在肺部良、恶性病变中的诊断应用［J］. 实用肿瘤杂志, 2007, 22(5): 461463. ［3］ Abe K, Baba S, Kaneko K, et al. Diagnostic and prognostic values of FDGPET in patients with nonsmall cell lung cancer［J］. Clin Imaging, 2009, 33(2): 9095. DOI:10.1016/j.clinimag.2008.06.032 . ［4］ Kim SK, AllenAuerbach M, Goldin J, et al. Accuracy of PET/CT in characterization of solitary pulmonary lesions［J］. J Nucl Med, 2007, 48(2): 214220. ［5］ Imai K, Minamiya Y, Saito H, et al. Diagnostic imaging in the preoperative management of lung cancer［J］. Surg Today, 2014, 44(7): 11971206. DOI:10.1007/s005950130660z. ［6］ De Wever W, Ceyssens S, Mortelmans L, et al. Additional value of PETCT in the staging of lung cancer: Comparison with CT alone, PET alone and visual correlation of PET and CT［J］. Eur Radiol, 2007, 17(1)： 2332. DOI:10.1007/s0033000602844. ［7］ Chao F, Zhang H. PET/CT in the staging of the nonsmallcell lung cancer［J］. J Biomed Biotechnol, 2012, 2012, 783739. DOI:10.1155/2012/783739. ［8］ Shim SS, Lee KS, Kim BT, et al. Nonsmall cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging［J］. Radiology, 2005, 236(3): 10111019. DOI:10.1148/radiol.2363041310. ［9］ Billé A, Pelosi E, Skanjeti A, et al . Preoperative intrathoracic lymph node staging in patients with nonsmallcell lung cancer: accuracy of integrated positron emission tomography and computed tomography［J］. Eur J Cardiothorac Surg, 2009, 36(3)： 440445. DOI:10.1016/j.ejcts.2009.04.003. ［10］ Liu N, Ma L, Zhou W, et al. Bone metastasis in patients with nonsmall cell lung cancer: The diagnostic role of F18FDG PET/CT［J］. Eur J Radiol, 2010, 74(1): 231235. DOI:10.1016/j.ejrad.2009.01.036. ［11］ Ettinger DS, Akerley W, Bepler G, et al. Nonsmall cell lung cancer［J］. J Natl Compr Canc Netw, 2010, 8(7): 740801. ［12］ Verhagen AF, Bootamab GP, TjanHeijnen VC, et al . FDGPET in staging lung cancer: How does it change the algorithm?［J］. Lung Cancer, 2004, 44(2): 175181. DOI:10.1016/j.lungcan.2003.11.007. ［13］ Rizzo G, Cattaneo GM, Castellone P, et al . Multimodal medical image integration to optimize radiotherapy planning in lung cancer treatment［J］. Ann Biomed Eng, 2004, 32(10): 13991408. ［14］ Mutlu H, Buyukcelik A, Erden A, et al . Staging with PETCT in patients with locally advanced non small cell lung cancer is superior to conventional staging methods in terms of survival［J］. Asian Pac J Cancer Prev, 2013, 14(6): 37433746. ［15］ Abramyuk A, Appold S, Zphel K, et al . Quantitative modificationgs of TNM staging,clinical staging and therapeutic intent by FDGPET/CT in patients with nonsmall cell lung cancer scheduled for radiotherapy—a retrospective study［J］. Lung Cancer, 2012, 78(2): 148152. DOI:10.1016/j.lungcan.2012.08.001. ［16］ Machtay M, Duan F, Siegel BA, et al . Prediction of survival by ［18F］fluorodeoxyglucose positron emission tomography in patients with locally advanced nonsmall cell lung cancer undergoing definitive chemoradiation therapy :results of the ACRIN 6668/RTOG 0235 trial［J］. J Clin Oncol, 2013, 31(30): 38233830. DOI:10.1200/JCO.2012.47.5947. ［17］ Hoekstra CJ, Stroobants SG, Smit EF, et al . Prognostic relevance of response evaluation using 18F2fluoro2deoxydglucose positron emission tomography in patients with locally advanced nonsmallcell lung cancer［J］. J Clin Oncol, 2005, 23(33): 83628370. ［18］ Lee DH, Kim S, Lee HY, et al . Early prediction of response to firstline therapy using integrated 18FFDG PET/CT for patients with advanced/metastatic nonsmall cell lung cancer［J］. J Thorac Oncol, 2009, 4(7): 816821. DOI:10.1097/JTO.0b013e3181a99fde. ［19］ Huang W, Zhou T, Ma L, et al . Standard uptake value and metabolic tumor volume of 18FFDG PET/CT predict shortterm outcome early in the course of chemoradiotherapy in advanced nonsmall cell lung cancer［J］. Eur J Nucl Med Mol Imaging, 2011, 38(9): 16281635. DOI:10.1007/s0025901118385. ［20］ van Elmpt W, Ollers M, Dingemans AM, et al. Response assessment using 18FFDG PET early in the course of radiotherapy correlates with survival in advancedstage nonsmall cell lung cancer［J］. J Nucl Med, 2012, 53(10): 15141520. DOI:10.2967/jnumed.111.102566. ［21］张华琦, 于金明, 孟雪，等. 18F氟脱氧葡萄糖PETCT显像预测Ⅲ期非小细胞肺癌的预后［J］．中华肿瘤杂志, 2012, 32(8): 603606. ［22］ Benz MR, Herrmann K, Walter F, et al . (18)FFDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib ［J］. J Nucl Med, 2011, 52(11): 16841689. DOI:0.2967/jnumed.111.095257. ［23］ Aukema TS, Kappers I, Olmos RA, et al. Is 18FFDG PET/CT useful for the early prediction of histopathologic response to neoadjuvant erlotinib in patients with nonsmall cell lung cancer?［J］. J Nucl Med, 2010, 51(9): 13441348. DOI:10.2967/jnumed.110.076224. ［24］ Mileshkin L, Hicks RJ, Hughes BG, et al . Changes in 18Ffluorodeoxyglucose and 18Ffluorodeoxythymidine positron emission tomography imaging in patients with nonsmall cell lung cancer treated with erlotinib［J］. Clin Cancer Res, 2011, 17(10): 33043315. DOI:10.1158/10780432.CCR102763. ［25］ Zander T, Scheffler M, Nogova L, et al. Early prediction of nonprogression in advanced nonsmallcell lung cancer treated with erlotinib by using ［(18)F］fluorodeoxyglucose and ［(18)F］fluorothymidine positron emission tomography［J］. J Clin Oncol, 2011, 29(13): 17011708. DOI:17011708. 10.1200/JCO.2010.32.4939. ［26］ Puranik AD, Purandare NC, Shah S, et al . Role of FDG PET/CT in assessing response to targeted therapy in metastatic lung cancers: Morphological versus metabolic criteria［J］. Indian J Nucl Med, 2015, 30(1): 2125. DOI:10.4103/09723919.147529. ［27］ Calais J, Thureau S, Dubray B, et al. Areas of high 18FFDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for nonsmall cell lung cancer［J］. J Nucl Med, 2015, 56(2):196203. DOI:10.2967/jnumed.114.144253. ［28］ Machtay M, Paulus R, Moughan J, et al . Defining localregional control and its importance in locally advanced nonsmall cell lung carcinoma［J］. J Thorac Oncol, 2012, 7(4): 716722. DOI:10.1097/JTO.0b013e3182429682. ［29］ Truong MT, Pan T, Erasmus JJ. Pitfalls in integrated CTPET of the thorax: implications in oncologic imaging［J］. J Thorac Imaging, 2006, 21(2): 111122. ［30］ Ikushima H, Dong L, Erasmus J, et al . Predictive value of 18F fluorodeoxyglucose up take by positron emission tomography for nonsmall cell lung cancer patients treated with radical radiotherapy［J］. J Radiat Res, 2010, 51(4): 465471. ［31］魏雪梅, 张云, 杨晓红, 等. 18FFDG PETCT 诊断肺部病变的误诊分析［J］．临床肺科杂志, 2012, 17(8): 14011403．［32］ Zhu SH, Zhang Y, Yu YH, et al . FDG PETCT in nonsmall cell lung cancer: relationship between primary tumor FDG uptake and extensional or metastatic potential［J］. Asian Pac J Cancer Prev, 2013, 14(5): 29252929. ［33］ Svik A, Malinen E, Olsen DR. Adapting biological feedback in radiotherapy［J］. Semin Radiat Oncol, 2010, 20(2): 138146. DOI:10.1016/j.semradonc.2009.11.008.

[1]	Zeng Liwu, Du Yuqiang, Zhang Peng, Tao Kaixiong. Progress in imaging evaluation of lateral lymph node metastasis in rectal cancer [J]. Journal of International Oncology, 2023, 50(4): 248-251.
[2]	Chen Yu, Xu Hua, Liu Hai, Chen Shixin. Construction of pathological classification prediction model for malignant pulmonary pure ground-glass nodule patients based on CT imaging [J]. Journal of International Oncology, 2023, 50(11): 655-660.
[3]	Song Tongjun, Deng Rui, Fei Lei, Lei Jinhua, Cao Fengjun. Comparison of the efficacy and safety of percutaneous needle biopsy of pulmonary or pleural lesions guided by CT and ultrasound [J]. Journal of International Oncology, 2022, 49(9): 526-531.
[4]	Li Jinhao, Wang Guidong, Li Xuefei, Liu Zilin, Meng Kailong. Clinical study of venous phase CT value in predicting central group lymph node metastasis of papillary thyroid carcinoma [J]. Journal of International Oncology, 2022, 49(10): 581-585.
[5]	Yang Jiankai, Huo Haoran, Sun Guozhu, Fan Zhenzeng, Jiao Baohua. Application of optical coherency tomography in tumor diagnosis and treatment [J]. Journal of International Oncology, 2021, 48(5): 287-291.
[6]	Wang Jiali, Han Dong, Chen Ying, Zhang Yamin, Ai Meimei. Construction of a nomogram of overall survival of patients with clear cell renal cell carcinoma based on preoperative CT findings [J]. Journal of International Oncology, 2020, 47(8): 480-486.
[7]	Jiang Jinquan, Liu Teli, Xia Lei, Zhu Hua, Yang Zhi. PET probes of small molecule polypeptide immunosuppressive agents guiding tumor immunotherapy [J]. Journal of International Oncology, 2019, 46(8): 449-452.
[8]	Song Zhe, Li Wei, Jia Nan, He Xiang, Zhou Wenyong. Value of perfusion CT quantitative analysis for predicting tumor regression grade after chemoradiotherapy in patients with rectal cancer [J]. Journal of International Oncology, 2019, 46(8): 480-484.
[9]	Liu Xiaocheng1, Li Chuangui1, Li Weitian2. Curative effect of TACE combined with Antike in the treatment of primary liver cancer [J]. Journal of International Oncology, 2019, 46(4): 226-230.
[10]	Guo Tianhui, Wang Haoming, Ren Ruimei, Xu Jinpeng, Song Hao, Xiao Wenjing, Xu Mingjin, Liu Xiguang. Progress of radiomics and radiogenomics in lung cancer [J]. Journal of International Oncology, 2018, 45(8): 566-569.
[11]	Ma Yi, Xu Shun. Pulmonary adenocarcinoma shown as groundglass nodule: radiology, histopathology and molecular biology characteristics [J]. Journal of International Oncology, 2018, 45(10): 627-631.
[12]	Nan Jing. Value of multislice spiral CT in differential diagnosis of pure groundglass nodule of 1 cm or less in lung infiltrating adenocarcinoma and before infiltration [J]. Journal of International Oncology, 2017, 44(8): 573-577.
[13]	Lu Rongzeng, Liu Jianshan, Lei Xing, Gao Yongtao, Gao Hongyan, Bai Tiecheng. Applacation of imaging examination in the preoperative staging diagnosis of colorectal cancer [J]. Journal of International Oncology, 2017, 44(8): 622-625.
[14]	LI Si-Yuan, XU Wen-Gui, TONG Guan-Sheng, ZHANG Li, WEN Zhe. Value of 18FFDG PET/CT in evaluation of curative effect and progressionfree survival on lymphoma [J]. Journal of International Oncology, 2017, 44(5): 361-365.
[15]	Wu Yuan, Liu Xiaolan, Su Liping. The clinical utility of 18F-FDG PET-CT for detection of bone marrow infiltration in lymphoma [J]. Journal of International Oncology, 2016, 43(8): 634-637.